希玛医疗二零二四年中期报告

2024INTERIM REPORT中期報告 Corporate Information2公司資料 Financial Highlights5財務概要 Management Discussion and Analysis6管理層討論及分析 Interim Condensed Consolidated Statement of Comprehensive Income27中期簡明綜合全面收益表 Interim Condensed Consolidated Statement of Financial Position29中期簡明綜合財務狀況表 Interim Condensed Consolidated Statement of Changes in Equity31中期簡明綜合權益變動表 Interim Condensed Consolidated Statement of Cash Flows33中期簡明綜合現金流量表 Notes to the Interim Condensed Consolidated Financial Information35中期簡明綜合財務資料附註 Report on Review of Interim Financial Information84中期財務資料的審閱報告 Other Information86其他資料 Corporate Information公司資料 董事會 BOARD OF DIRECTORSExecutive Directors 執行董事林順潮醫生（主席兼行政總裁）李肖婷女士李佑榮醫生 Dr. LAM Shun Chiu Dennis(Chairman and Chief Executive Officer)Ms. LI XiaotingDr. LEE Yau Wing Vincent 獨立非執行董事歐陽伯權博士（副主席）馬照祥先生葉澍堃先生殷可先生 Independent Non-executive Directors Dr. Rex AUYEUNG Pak-kuen(Vice Chairman)Mr. MA Andrew Chiu CheungMr. IP Shu Kwan StephenMr. YIN Ke BOARD COMMITTEESAudit Committee 董事會委員會審核委員會馬照祥先生（主席）葉澍堃先生殷可先生 Mr. MA Andrew Chiu Cheung(Chairperson)Mr. IP Shu Kwan StephenMr. YIN Ke 薪酬委員會葉澍堃先生（主席）李肖婷女士馬照祥先生 Remuneration CommitteeMr. IP Shu Kwan Stephen(Chairperson)Ms. LI XiaotingMr. MA Andrew Chiu Cheung 提名委員會 歐陽伯權博士（主席）馬照祥先生殷可先生 Nomination CommitteeDr. Rex AUYEUNG Pak-kuen(Chairperson)Mr. MA Andrew Chiu CheungMr. YIN Ke 授權代表李肖婷女士陳華平先生 AUTHORIZED REPRESENTATIVES Ms. LI XiaotingMr. CHAN Wa Ping 公司秘書陳華平先生 COMPANY SECRETARYMr. CHAN Wa Ping 核數師 AUDITOR 羅兵咸永道會計師事務所執業會計師註冊公眾利益實體核數師香港中環太子大廈22樓 PricewaterhouseCoopersCertified Public AccountantsRegistered Public Interest Entity Auditor22/F, Prince’s BuildingCentralHong Kong 註冊辦事處 REGISTERED OFFICE Cricket Square, Hutchins DriveP.O. Box 2681 Grand CaymanKY1-1111Cayman Islands Cricket Square, Hutchins DriveP.O. Box 2681 Grand CaymanKY1-1111Cayman Islands 香港主要營業地點及總部 PRINCIPAL PLACE OF BUSINESS AND HEADOFFICE IN HONG KONG 香港畢打街1–3號中建大廈1535室 Suite 1535, Central Building1–3 Pedder StreetHong Kong 股份過戶登記總處 PRINCIPAL SHARE REGISTRAR Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins DriveP.O. Box 2681Grand Cayman, KY1-1111Cayman Islands Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins DriveP.O. Box 2681Grand Cayman, KY1-1111Cayman Islands Corporate Information公司資料 HONG KONG BRANCH SHARE REGISTRAR 香港股份過戶登記分處 香港中央證券登記有限公司香港灣仔皇后大道東183號合和中心17樓1712–1716號舖 Computershare Hong Kong Investor Services LimitedShops 1712–1716, 17th FloorHopewell Centre183 Queen’s Road EastWanchaiHong Kong PRINCIPAL BANKERS 主要往來銀行 The Bank of East Asia, LimitedBank of China (Hong Kong) LimitedBank of Communications Co., Ltd.Industrial and Commercial Bank of China LimitedThe Hongkong and Shanghai Banking Corporation Limited 東亞銀行有限公司中國銀行（香港）有限公司交通銀行股份有限公司中國工商銀行股份有限公司香港上海滙豐銀行有限公司 LEGAL ADVISOR ON HONG KONG LAWS 香港法律顧問 方達律師事務所香港中環康樂廣場8號交易廣場1期26樓 Fangda Partners26th Floor, One Exchange Square8 Connaught PlaceCentral, Hong Kong COMPANY WEBSITEwww.cmermedical.com 公司網站www.cmermedical.com 股份代號03309 STOCK CODE03309 Management Discussion and Analysis管理層討論及分析 業務回顧 BUSINESS REVIEWOverview 概覽 As a result of the improvement of the quality of the overallbusiness operations and better cost control, the Group’sprofitability improved in for the six months ended 30 June2024 (“1H2024”). Excluding the profit from the sales ofmedical consumables segment, the profit for the periodattributable to equity holders of the Company from our coremedical service increased by 31.7% to HK$30.8 million in1H2024 as compared to HK$23.4 million for the same periodlast year. Profit for the period attributable to equity holdersof the Company increased by 3.4% to HK$30.8 million in1H2024 as compared to HK$29.8 million for the same periodlast year. 由於整體業務營運質素提升及成本控制，本集團於截至2024年6月30日止六個月（「2024年上半年」）的盈利能力有所改善。撇除銷售醫療耗材分部的利潤，2024年上半年來自核心醫療服務的本公司權益持有人應佔期內利潤由去年同期的23.4百萬港元增加31.7%至30.8百萬港元。2024年上半年的本公司權益持有人應佔期內利潤由去年同期的29.8百萬港元增加3.4%至30.8百萬港元。 Compared with the same period last year, our core medicalservice revenue (comprising the provision of ophthalmicservices, the provision of dental and other medical servicesand the sales of vision aid products) decreased slightly by0.9% to HK$922.5 million in 1H2024 from HK$930.8 millionfor the same period last year. The slight decrease in revenueis the combined result of the decrease in the revenuegenerated from the ophthalmic services in both Hong Kongand Mainland China due to the negative market sentimentand the economic uncertainties, and the increase in revenuegenerated from the dental services in Shenzhen under thebrand“Shenzhen CKJ”driven by the trend of cross-borderconsumption by Hong Kong citizens in Shenzhen. 我們核心醫療服務的收益（包括提供眼科服務、提供牙科及其他醫療服務以及銷售視力輔助產品）由去年同期的930.8百萬港元略為減少0.9%至922.5百萬港元。收益略為減少乃由於香港及中國內地的眼科服務所得收益因市場情緒負面及經濟不確定因素而減少以及深圳牙科服務旗下品牌「深圳愛康健」所得收益因港人跨境前往深圳消費的趨勢而增加的綜合結果所致。 The Group has been closely monitoring the market conditionand adjusting its business strategies to prioritize ourcore business segments, while effectiv